• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Diabetes: Medtronic joins $44m round for Semma Therapeutics

March 25, 2015 By Brad Perriello

Medtronic joins $44m round for Semma Therapeutics

Medtronic (NYSE:MDT) is among a cadre of investors backing a $44 million Series A round for Semma Therapeutics, a startup developing a cell therapy-device treatment for Type 1 diabetes.

MPM Capital led the round for Cambridge, Mass.-based Semma. Fidelity Biosciences and Arch Venture Partners also participated.

In conjunction with equity financing, Semma also inked an agreement with Novartis (NYSE:NVS) that’s expected to advance the program through human proof-of-concept, the compan said.

Scientific founder Doug Melton is co-chair of the Harvard University’s Stem Cell & Regenerative Biology department. Melton’s lab work identified a way to produce billions of functional, insulin-producing beta cells in the laboratory.

That technology is exclusively licensed to Semma with an eye on developing a cell-based treatment for diabetes. Researchers envision combining the cells with a medical device that would help replace missing beta cells in diabetic patients without immunosuppression, Semma said.

"The ability to generate glucose-responsive, human beta cells through controlled differentiation of stem cells will accelerate the development of new therapeutics and I am thrilled and honored to be part of it," new CEO Robert Millman, co-founder of Semma and MPM Capital managing director, said in prepared remarks. "We have assembled an experienced team with a track record of success in drug development. Our goal is to ensure we bring this remarkable discovery to patients as quickly as possible to reduce or eliminate their reliance on daily insulin injections."

Medtronic’s Dr. Stephen Oesterle, senior vice president for medicine & technology, joined Semma as a board observer, Semma said.

Medtronic earlier this month invested in another diabetes-focused company, Glooko, joining its $16.5 million Series B round. Glooko is developing diabetes management software designed to link more than 30 blood glucose testing systems with smartphones.

Filed Under: Discovery, Drug-Device Combinations Tagged With: Harvard University, Semma Therapeutics

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS